Author index*

A

Aarbakke J (*see* Loennechen T). 2001;70:183-8
Abdel-Rahman SM (*see* de Wildt et al). 2001;70:525-31
Abernethy DR. Reply. 2001;70:568
Aderjan R (*see* Tayrouz et al). 2001;70:405-414
Agnew JR (*see* Phillips et al). 2001;70:370-83
Ahonen J (*see* Jokinen et al). 2001;70:344-50
Almog S (*see* Loebstein et al). 2001;70:159-64
Althaus M (*see* de Mey et al). 2001;70:142-8
Alves S, Amorim A, Ferreira F, Prata MJ. Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity. 2001;70:165-74
Amorim A (*see* Alves et al). 2001;70:165-74
Andersson K (*see* Laine et al). 2001;70:327-35
Arakawa M (*see* Sugimoto et al). 2001;70:518-24
Arnaud P (*see* Boulton et al). 2001;70:48-57
Averbuch M, Katzper M. Gender and the placebo analgesic effect in acute pain. 2001;70:287-91
Avila A (*see* Codner et al). 2001;70:91-8
Azie NE (*see* Fleishaker et al). 2001;70:261-9

B

Baas H (*see* Dietz et al). 2001;70:33-41
Bae KS (*see* Yu et al). 2001;70:228-36
Bailey DG (*see* Offman et all). 2001;70:17-23
Barbé F (*see* Maillard et al). 2001;70:540-5
Barclay ML (*see* von Richter et al). 2001;70:217-27
Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, Funck-Brentano C. Effect of grapefruit juice on digoxin pharmacokinetics in humans. 2001;70:311-5
Beijnen JH (*see* Kerbusch et al). 2001;70:132-41
Bend JR (*see* Offman et all). 2001;70:17-23
Benet LZ (*see* Tsunoda et al). 2001;70:462-7
Benowitz NL. Deficient C-oxidation of nicotine continued. 2001;70:567
Berman N (*see* Mendoza et al). 2001;70:552-60
Berthier S (*see* Kovarik et al). 2001;70:247-54
Bertilsson L (*see* Härtter et al). 2001;70:10-6
Bertilsson L (*see* Laine et al). 2001;70:327-35
Bon MAM (*see* Mulder et al). 2001;70:546-51
Bonagura VR (*see* Mirochnick et al). 2001;70:24-32
Born J (*see* Deininger et al). 2001;70:362-9
Boston R (*see* Cepeda et al). 2001;70:351-61
Boulton DW, Arnaud P, DeVane L. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. 2001;70:48-57
Boutroy MJ (*see* Maillard et al). 2001;70:540-5
Brahim JS (*see* Dionne et al). 2001;70:66-73
Brandolese R, Scordo MG, Spina E, Gusella M, Padrini R. Severe phenytoin intoxication in a subject homozygous for *CYP2C9*3*. 2001;70:391-4
Breteler M (*see* Salas et al). 2001;70:561-6
Brinkmann U (*see* Becquemont et al). 2001;70:311-6
Burhenne J (*see* Tayrouz et al). 2001;70:405-414

C

Cameron DW (*see* Gallicano et al). 2001;70:149-58
Capone ML (*see* Santini et al). 2001;70:475-83
Capparelli E (*see* Mirochnick et al). 2001;70:24-32
Carignan G (*see* Gallicano et al). 2001;70:149-58
Carr DB (*see* Cepeda et al). 2001;70:351-61
Cassorla F (*see* Codner et al). 2001;70:91-8
Cepeda MS, Farrar JT, Roa JH, Boston R, Meng QC, Ruiz F, Carr DB, Strom BL. Ethnicity influences morphine pharmacokinetics and pharmacodynamics. 2001;70:351-61
Cerchio K (*see* Codner et al). 2001;70:91-8
Chen XP (*see* Wang et al). 2001;70:42-7
Chen XP (*see* Zhu et al). 2001;70:455-61
Chiou WL, Jeong H, Wu TC, Ma C. Reply. 2001;70:397-8
Chiou WL, Jeong HY, Wu TC, Ma C. Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization. 2001;70:305-10
Cho JY (*see* Yu et al). 2001;70:228-36
Choo EF (*see* Kim et al). 2001;70:189-99
Christensen M (*see* Härtter et al). 2001;70:10-6
Christians U (*see* Tsunoda et al). 2001;70:462-7
Chu J (*see* Henderson et al). 2001;70:567-8
Codner E, Cassorla F, Tiupakov AN, Mericq MV, Avila A, Pescovitz OH, Svensson J, Cerchio K, Krupa D, Gertz BJ, Murphy G. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. 2001;70:91-8
Coon JT (*see* Ernst and Coon). 2001;70:497-504
Cooper E (*see* Mirochnick et al). 2001;70:24-32

D

Dalhoff K (*see* Schmidt et al). 2001;70:446-54
Darville TL (*see* James et al). 2001;70:280-6
de Mey C, Althaus M, Ezan E, Retzow A. Erythromycin increases plasma concentrations of α-dihydroergocryptine in humans. 2001;70:142-8
de Vries-Hanje JC (*see* Thijssen et al). 2001;70:292-8
de Wildt SN, Kearns GL, Hop WCJ, Murry DJ, Abdel-Rahman SM, van den Anker JN. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. 2001;70:525-31
Deininger E, Oltmanns KM, Wellhoener P, Fruehwald-Schultes B, Kern W, Heuer B, Dominiak P, Born J, Fehm HL, Peters A. Losartan attenuates symptomatic and hormonal responses to hypoglycemia in humans. 2001;70:362-9
Dent J (*see* von Richter et al). 2001;70:217-27
DeVane L (*see* Boulton et al). 2001;70:48-57
Dietz M, Harder S, Graff J, Künig G, Vontobel P, Leenders KL, Baas H. Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[^{18}F]levodopa positron emission tomography in patients with Parkinson's disease. 2001;70:33-41
Dilzer SC (*see* Kovarik et al). 2001;70:425-30
Ding R (*see* Tayrouz et al). 2001;70:405-414
Dionne RA, Lepinski AM, Gordon SM, Jaber L, Brahim JS, Hargreaves KM. Analgesic effects of peripherally administered opioids in clinical models of acute and chronic inflammation. 2001;70:66-73
Dishy V, Sofowara G, Harris PA, Kandcer M, Zhan F, Wood AJJ, Stein CM. The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. 2001;70:270-9
Dominiak P (*see* Deininger et al). 2001;70:362-9
Dresser GK (*see* Kim et al). 2001;70:189-99
Dresser GK (*see* Offman et all). 2001;70:17-23
Drittij MJ (*see* Thijssen et al). 2001;70:292-8

*July, pp. 1-102; August, pp. 103-204; September, pp. 205-304; October, pp. 305-404; November, pp. 405-496; December, pp. 497-586. Index to the ASCPT meeting abstracts is located in the February issue.

du Souich P, Vergés J. Simple approach to predict the maximal effect elicited by a drug when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data. 2001;70:5-9.
Duvaldestin P. Limited sampling approach. 2001;70:493

E

Eichelbaum M (*see* von Richter et al). 2001;70:217-27
Endemann D (*see* Kammerl et al). 2001;70:468-74
Ernst E, Coon JT. Heavy metals in traditional Chinese medicines: a systematic review. 2001;70:497-504
Ezan E (*see* de Mey et al). 2001;70:142-8
Ezra D (*see* Loebstein et al). 2001;70:159-64

F

Farrar HC (*see* James et al). 2001;70:280-6
Farrar JT (*see* Cepeda et al). 2001;70:351-61
Fattinger K (see Rentsch et al). 2001;70:237-46
Fehm HL (*see* Deininger et al). 2001;70:362-9
Ferreira F (*see* Alves et al). 2001;70:165-74
Figueiredo J (*see* Kovarik et al). 2001;70:425-30
Fischereder M (*see* Kammerl et al). 2001;70:468-74
Fleishaker JC, Francom SF, Herman BD, Knuth DW, Azie NE. Lack of effect of reboxetine on cardiac repolarization. 2001;70:261-9
Francom SF (*see* Fleishaker et al). 2001;70:261-9
Fraser R (*see* von Richter et al). 2001;70:217-27
Freeman DJ (*see* Offman et all). 2001;70:17-23
Freeman RB (*see* Tsunoda et al). 2001;70:462-7
Fresson J (*see* Maillard et al). 2001;70:540-5
Fromm MF (*see* von Richter et al). 2001;70:217-27
Frossard M (*see* Joukhadar et al). 2001;70:532-9
Fruehwald-Schultes B (*see* Deininger et al). 2001;70:362-9
Fujimura A (*see* Sugimoto et al). 2001;70:518-24
Funck-Brentano C (*see* Becquemont et al). 2001;70:311-6
Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. Effect of high-dose lansoprazole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. 2001;70:484-92

G

Gallicano K, Khaliq Y, Carignan G, Tseng A, Walmsley S, Cameron DW. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. 2001;70:149-58
Ganssmann B (*see* Tayrouz et al). 2001;70:405-414
Geisslinger G (*see* Ihmsen et al). 2001;70:431-8
Gertz BJ (*see* Codner et al). 2001;70:91-8
Givens TG (*see* James et al). 2001;70:280-6
Gordon SM (*see* Dionne et al). 2001;70:66-73
Gorski JC (*see* Wang et al). 2001;70:317-26
Graff J (*see* Dietz et al). 2001;70:33-41
Grasela TH (*see* Phillips et al). 2001;70:370-83
Greiner B (*see* von Richter et al). 2001;70:217-27
Gusella M (*see* Brandolese et al). 2001;70:391-4

H

Haefeli WE (*see* Tayrouz et al). 2001;70:405-414
Halkin H (*see* Loebstein et al). 2001;70:159-64
Hall SD (*see* Wang et al). 2001;70:317-26
Hammam MA (*see* Wang et al). 2001;70:317-26
Harada K (*see* Sugimoto et al). 2001;70:518-24
Harder S (*see* Dietz et al). 2001;70:33-41
Hargreaves KM (*see* Dionne et al). 2001;70:66-73
Harris PA (*see* Dishy et al). 2001;70:270-9
Harris RZ (*see* Tsunoda et al). 2001;70:462-7
Härtter S (*see* Laine et al). 2001;70:327-35
Härtter S, Ursing C, Morita S, Tybring G, von Bahr C, Christensen M, Röjdmark S, Bertilsson L. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. 2001;70:10-6
Hartz I (*see* Loennechen T). 2001;70:183-8
Hascoët JM (*see* Maillard et al). 2001;70:540-5
He N (*see* Wang et al). 2001;70:42-7
He N (*see* Zhu et al). 2001;70:455-61
Henderson W, Chu J, Hoffman R. QTc prolongtion and drugs. 2001;70:567-8
Herats D (*see* Loebstein et al). 2001;70:159-64
Herman BD (*see* Fleishaker et al). 2001;70:261-9
Herrmann M (*see* Joukhadar et al). 2001;70:532-9
Heuer B (*see* Deininger et al). 2001;70:362-9
Higuchi S (*see* Shintani et al). 2001;70:175-82
Hinson JA (*see* James et al). 2001;70:280-6
Hoffman R (*see* Henderson et al). 2001;70:567-8
Hofman A (*see* Salas et al). 2001;70:561-6
Hop WCJ (*see* de Wildt et al). 2001;70:525-31
Houston JB (*see* Tucker et al). 2001;70:103-14
Hsu CH (*see* Kovarik et al). 2001;70:247-54
Huang SL (*see* Zhu et al). 2001;70:455-61
Huang SMB (*see* Tucker et al). 2001;70:103-14
Huang SM (*see* Wang et al). 2001;70:317-26
Huitema ADR (*see* Kerbusch et al). 2001;70:132-41

I

Ieiri I (*see* Shintani et al). 2001;70:175-82
Ihmsen H, Geisslinger G, Schüttler J. Stereoselective pharmacokinetics of ketamine: *R*(-)-ketamine inhibits the elimination of *S*(-)-ketamine. 2001;70:431-8
Inoue K (*see* Shintani et al). 2001;70:175-82
In't Veld BA (*see* Salas et al). 2001;70:561-6
Ishii Y (*see* Tsutsumi et al). 2001;70:121-5
Ishizaki T (*see* Furuta et al). 2001;70:484-92

J

Jaber L (*see* Dionne et al). 2001;70:66-73
Jacobus D (*see* Mirochnick et al). 2001;70:24-32
Jaillon P (*see* Becquemont et al). 2001;70:311-6
James LP, Farrar HC, Darville TL, Sullivan JE, Givens TG, Kearns GL, Wasserman GS, Simpson PM, Hinson JA, The Pediatric Pharmacology Research Network of the National Institute of Child Health and Human Development. Elevation of serum interleukin 8 levels in acetaminophen overdose in children and adolescents. 2001;70:280-6
Jang IJ (*see* Yu et al). 2001;70:228-36
Jansen M (*see* Kerbusch et al). 2001;70:132-41
Jansen RLH (*see* Kerbusch et al). 2001;70:132-41
Jeong H (*see* Chiou et al). 2001;70:397-8
Jeong HY (*see* Chiou et al). 2001;70:305-10
Joël SP (*see* Penson and Joel). 2001;70:493-4
Jokinen MJ, Olkkola KT, Ahonen J, Neuvonen PJ. Effect of rifampicin and tobacco smoking on the pharmacokinetics of ropivacaine. 2001;70:344-50
Joukhadar C, Klein N, Frossard M, Minar E, Stass H, Lackner E, Herrmann M, Riedmüller E, Müller M. Angioplasty increases target site concentrations of ciprofloxacin in patients with arterial occlusive disease. 2001;70:532-9
Jusko WJ (*see* Mager and Jusko). 2001;70:210-6

K

Kahan BD, Kramer WG. Median effect analysis of efficacy versus adverse effects of immunosuppressants. 2001;70:74-81
Kalow W. Pharmacogenetics, pharmacogenomics, and pharmacobiology. 2001;70:1-4
Kammerl MC, Nüsing RM, Schweda F, Endemann D, Stubanus M, Kees F, Lackner KJ, Fischereder M, Krämer BK. Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2. 2001;70:468-74
Kandcer M (*see* Dishy et al). 2001;70:270-9
Katzper M (*see* Averbuch and Katzper). 2001;70:287-91
Kawaguchi A (*see* Sugimoto et al). 2001;70:518-24

Kearns GL (*see* de Wildt et al). 2001;70:525-31
Kearns GL (*see* James et al). 2001;70:280-6
Kearns GL (*see* Van Overmeire et al). 2001;70:336-43
Kees F (*see* Kammerl et al). 2001;70:468-74
Kerb R (*see* Becquemont et al). 2001;70:311-6
Kerbusch T, Jansen RLH, Mathôt RAA, Huitema ADR, Jansen M, van Rijswijk REN, Beijnen JH. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. 2001;70:132-41
Kern W (*see* Deininger et al). 2001;70:362-9
Kersey K (*see* O'Connor-Semmes et al). 2001;70:126-31
Khaliq Y (*see* Gallicano et al). 2001;70:149-58
Kharasch ED (see Yao et al). 2001;70:415-24
Kharasch E (*see* Phimmasone and Kharasch). 2001;70:505-17
Kildalsen H (*see* Loennechen T). 2001;70:183-8
Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. Identification of functionally variant *MDR1* alleles among European Americans and African Americans. 2001;70:189-99
Kirkegaard P (*see* Schmidt et al). 2001;70:446-54
Kivistö KT (*see* Lapatto-Reiniluoto et al). 2001;70:255-60
Kivistö KT (*see* Niemi et al). 2001;70:439-45
Kivistö KT (*see* Niemi et al). 2001;70:58-65
Klein N (*see* Joukhadar et al). 2001;70:532-9
Klingmann A (*see* Tayrouz et al). 2001;70:405-414
Knuth DW (*see* Fleishaker et al). 2001;70:261-9
Koch KM (*see* O'Connor-Semmes et al). 2001;70:126-31
Kodama Y (*see* Tsutsumi et al). 2001;70:121-5
Kömhoff M (*see* Nüsing et al). 2001;70:384-90
Kotegawa T (*see* Tsutsumi et al). 2001;70:121-5
Kovarik JM, Hsu CH, McMahon L, Berthier S, Rordorf C. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. 2001;70:247-54
Kovarik JM, Sabia HD, Figueiredo J, Zimmermann H, Reynolds C, Dilzer SC, Lasseter K, Rordorf C. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. 2001;70:425-30
Krämer BK (*see* Kammerl et al). 2001;70:468-74
Kramer WG (*see* Kahan and Kramer). 2001;70:74-81
Krupa D (*see* Codner et al). 2001;70:91-8
Kubba SV (*see* Kim et al). 2001;70:189-99
Kullak-Ublick GA (*see* Rentsch et al). 2001;70:237-46
Künig G (*see* Dietz et al). 2001;70:33-41
Kunze K (*see* Yao et al). 2001;70:415-24
Kuranari M (*see* Tsutsumi et al). 2001;70:121-5

L

Lackner E (*see* Joukhadar et al). 2001;70:532-9
Lackner KJ (*see* Kammerl et al). 2001;70:468-74
Laine K, Tybring G, Härtter S, Andersson K, Svensson JO, Widén J, Bertilsson L. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the
debrisoquin test. 2001;70:327-35
Lam R (*see* O'Connor-Semmes et al). 2001;70:126-31
Lan LB (*see* Kim et al). 2001;70:189-99
Lapatto-Reiniluoto O, Kivistö KT, Neuvonen PJ. Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs. 2001;70:255-60
Lasseter K (*see* Kovarik et al). 2001;70:425-30
Leake BF (*see* Kim et al). 2001;70:189-99
Lebot M (*see* Becquemont et al). 2001;70:311-6
Leenders KL (*see* Dietz et al). 2001;70:33-41
Lepinski AM (*see* Dionne et al). 2001;70:66-73
Lesko LJ (*see* Wang et al). 2001;70:317-26
Levy RH (*see* Yao et al). 2001;70:415-24
Lim HS (*see* Yu et al). 2001;70:228-36
Lin KM (*see* Mendoza et al). 2001;70:552-60
Lindsey J (*see* Mirochnick et al). 2001;70:24-32
Liu ZQ (*see* Wang et al). 2001;70:42-7
Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J, Herats D, Halkin H, Ezra D. Interindividual variability in sensitivity to warfarin-nature or nurture? 2001;70:159-64
Loennechen T, Utsi E, Hartz I, Lysaa R, Kildalsen H, Aarbakke J. Detection of one single mutation predicts thiopurine S-methyltransferase activity in a population of Saami in northern Norway. 2001;70:183-8
Lubetsky A (*see* Loebstein et al). 2001;70:159-64
Ludwig EA (*see* Phillips et al). 2001;70:370-83
Lysaa R (*see* Loennechen T). 2001;70:183-8

M

Ma C (*see* Chiou et al). 2001;70:305-10
Ma C (*see* Chiou et al). 2001;70:397-8
Mager DE, Jusko WJ. Pharmacodynamic modeling of time-dependent transduction systems. 2001;70:210-6
Maillard C, Boutroy MJ, Fresson J, Barbé F, Hascoët JM. QT interval lengthening in premature infants treated with doxapram. 2001;70:540-5
Mamiya K (*see* Shintani et al). 2001;70:175-82
Masada M (*see* Sugimoto et al). 2001;70:518-24
Mathôt RAA (*see* Kerbusch et al). 2001;70:132-41
Matsuki S (*see* Tsutsumi et al). 2001;70:121-5
McIntosh K (*see* Mirochnick et al). 2001;70:24-32
McKinsey J (*see* Kim et al). 2001;70:189-99
McMahon L (*see* Kovarik et al). 2001;70:247-54
Meier PJ (*see* Rentsch et al). 2001;70:237-46
Mendoza R, Wan YJY, Poland RE, Smith M, Zheng Y, Berman N, Lin KM. CYP2D6 polymorphism in a Mexican American population. 2001;70:552-60
Meng QC (*see* Cepeda et al). 2001;70:351-61
Mericq MV (*see* Codner et al). 2001;70:91-8
Mikus G (*see* Tayrouz et al). 2001;70:405-414
Minar E (*see* Joukhadar et al). 2001;70:532-9
Mirochnick M, Cooper E, Capparelli E, McIntosh K, Lindsey J, Xu J, Jacobus D, Mofenson L, Bonagura VR, Nachman S, Yogev R, Sullivan JL, Spector SA. Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection. 2001;70: 24-32
Miyakawa I (*see* Tsutsumi et al). 2001;70:121-5
Miyamori I (*see* Sugimoto et al). 2001;70:518-24
Mofenson L (*see* Mirochnick et al). 2001;70:24-32
Morita S (*see* Härtter et al). 2001;70:10-6
Mulder AB, van Lijf HJ, Bon MAM, van den Bergh FAJTM, Touw DJ, Neef C, Vermes I. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. 2001;70:546-51
Müller M (*see* Joukhadar et al). 2001;70:532-9
Munoz C (*see* Offman et all). 2001;70:17-23
Murphy G (*see* Codner et al). 2001;70:91-8
Murry DJ (*see* de Wildt et al). 2001;70:525-31

N

Nachman S (*see* Mirochnick et al). 2001;70:24-32
Nakano S (*see* Tsutsumi et al). 2001;70:121-5
Neef C (*see* Mulder et al). 2001;70:546-51
Neuvonen PJ (*see* Jokinen et al). 2001;70:344-50
Neuvonen PJ (*see* Lapatto-Reiniluoto et al). 2001;70:255-60
Neuvonen PJ (*see* Niemi et al). 2001;70:439-45
Neuvonen PJ (*see* Niemi et al). 2001;70:58-65
Niemi M, Neuvonen PJ, Kivistö KT. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. 2001;70:439-45
Niemi M, Neuvonen PJ, Kivistö KT. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentration and effects of repaglinide. 2001;70:58-65
Ninomiya H (*see* Shintani et al). 2001;70:175-82
Nishiki K (*see* Sugimoto et al). 2001;70:518-24
Nüsing RM, Reinalter SC, Peters M, Kömhoff M, Seyberth HW. Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide. 2001;70:384-90

Nüsing RM (*see* Kammerl et al). 2001;70:468-74

O

O'Connor-Semmes RL, Kersey K, Williams DH, Lam R, Koch KM. Effect of ranitidine on the pharmacokinetics of triazolam and α-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people. 2001;70:126-31

Offman EM, Freeman DJ, Dresser GK, Munoz C, Bend JR, Bailey DG. Red wine-cisapride interaction: comparison with grapefruit juice. 2001;70:17-23

Ohashi K (*see* Furuta et al). 2001;70:484-92

Ohmori M (*see* Sugimoto et al). 2001;70:518-24

Olkkola KT (*see* Jokinen et al). 2001;70:344-50

Olsen AK (*see* Schmidt et al). 2001;70:446-54

Oltmanns KM (see Deininger et al). 2001;70:362-9

Omari T (*see* von Richter et al). 2001;70:217-27

Otsubo K (*see* Shintani et al). 2001;70:175-82

Ou-Yang DS (*see* Zhu et al). 2001;70:455-61

P

Padrini R (*see* Brandolese et al). 2001;70:391-4

Panara MR (*see* Santini et al). 2001;70:475-83

Patrignani P (*see* Santini et al). 2001;70:475-83

Patrono C (*see* Santini et al). 2001;70:475-83

The Pediatric Pharmacology Research Network of the National Institute of Child Health and Human Development (*see* James et al). 2001;70:280-6

Peleg D (*see* Loebstein et al). 2001;70:159-64

Penson RT, Joel SP. Reply. 2001;70:493-4

Pescovitz OH (*see* Codner et al). 2001;70:91-8

Peters A (*see* Deininger et al). 2001;70:362-9

Peters M (*see* Nüsing et al). 2001;70:384-90

Phillips L, Grasela TH, Agnew JR, Ludwig EA, Thompson GA. A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide. 2001;70:370-83

Phimmasone S, Kharasch E. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. 2001;70:505-17

Pluim MAL (*see* van der Marel et al). 2001;70:82-90

Poland RE (*see* Mendoza et al). 2001;70:552-60

Prata MJ (*see* Alves et al). 2001;70:165-74

R

Ragueneau I (*see* Yao et al). 2001;70:415-24

Rasmussen A (*see* Schmidt et al). 2001;70:446-54

Reichel C (*see* Rentsch et al). 2001;70:237-46

Reidenberg J (*see* Reidenberg and Reidenberg). 2001;70:299-301

Reidenberg MM. An open invitation for an explanation about how drug prices are set. 2001;70:205-7

Reidenberg MM, Reidenberg J. *Clinical Pharmacology & Therapeutics* annual report 2000. 2001;70:299-301

Reidenberg MM. Unmasking ghost writers. 2001;70:208-9

Reinalter SC (*see* Nüsing et al). 2001;70:384-90

Rentsch KM, Kullak-Ublick GA, Reichel C, Meier PJ, Fattinger K. Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics. 2001;70:237-46

Retzow A (*see* de Mey et al). 2001;70:142-8

Reynolds C (*see* Kovarik et al). 2001;70:425-30

Ricciotti E (*see* Santini et al). 2001;70:475-83

Riedmüller E (*see* Joukhadar et al). 2001;70:532-9

Rivory LP, Watkins PB. Erythromycin breath test. 2001;70:395-6

Roa JH (*see* Cepeda et al). 2001;70:351-61

Roitelman J (*see* Loebstein et al). 2001;70:159-64

Röjdmark S (*see* Härtter et al). 2001;70:10-6

Rordorf C (*see* Kovarik et al). 2001;70:247-54

Rordorf C (*see* Kovarik et al). 2001;70:425-30

Rotenberg M (*see* Loebstein et al). 2001;70:159-64

Ruiz F (*see* Cepeda et al). 2001;70:351-61

S

Sabia HD (*see* Kovarik et al). 2001;70:425-30

Sakamoto K (*see* Sugimoto et al). 2001;70:518-24

Salas M, In't Veld BA, van der Linden PD, Hofman A, Breteler M, Stricker BHC. Impaired cognitive function and compliance with antihypertensives in elderly: the Rotterdam Study. 2001;70:561-6

Santini GA, Patrignani P, Sciulli MG, Seta F, Tacconelli S, Panara MR, Ricciotti E, Capone ML, Patrono C. The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. 2001;70:475-83

Schepens PJC (*see* Van Overmeire et al). 2001;70:336-43

Schmidt LE, Olsen AK, Stentoft K, Rasmussen A, Kirkegaard P, Dalhoff K. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients. 2001;70:446-54

Schuetz EG (*see* Kim et al). 2001;70:189-99

Schuetz JD (*see* Kim et al). 2001;70:189-99

Schüttler J (*see* Ihmsen et al). 2001;70:431-8

Schwarz UI (*see* Kim et al). 2001;70:189-99

Schweda F (*see* Kammerl et al). 2001;70:468-74

Sciulli MG (*see* Santini et al). 2001;70:475-83

Scoones G (*see* van der Marel et al). 2001;70:82-90

Scordo MG (*see* Brandolese et al). 2001;70:391-4

Seta F (*see* Santini et al). 2001;70:475-83

Seyberth HW (*see* Nüsing et al). 2001;70:384-90

Shin SG (*see* Yu et al). 2001;70:228-36

Shintani M, Ieiri I, Inoue K, Mamiya K, Ninomiya H, Tashiro N, Higuchi S, Otsubo K. Genetic polymorphisms and functional characterization of the 5′-flanking region of the human *CYP2C9* gene: in vitro and in vivo studies. 2001;70:175-82

Shirai N (*see* Furuta et al). 2001;70:484-92

Shon JH (*see* Yu et al). 2001;70:228-36

Shu Y (*see* Wang et al). 2001;70:42-7

Simpson PM (*see* James et al). 2001;70:280-6

Smith M (*see* Mendoza et al). 2001;70:552-60

Sofowara G (*see* Dishy et al). 2001;70:270-9

Somogyi AA (*see* von Richter et al). 2001;70:217-27

Spector SA (*see* Mirochnick et al). 2001;70:24-32

Spina E (*see* Brandolese et al). 2001;70:391-4

Stass H (*see* Joukhadar et al). 2001;70:532-9

Stein CM (*see* Dishy et al). 2001;70:270-9

Stentoft K (*see* Schmidt et al). 2001;70:446-54

Stricker BHC (*see* Salas et al). 2001;70:561-6

Strom BL (*see* Cepeda et al). 2001;70:351-61

Stubanus M (*see* Kammerl et al). 2001;70:468-74

Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, Fujimura A. Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin. 2001;70:518-24

Sullivan JE (*see* James et al). 2001;70:280-6

Sullivan JL (*see* Mirochnick et al). 2001;70:24-32

Svensson JO (*see* Laine et al). 2001;70:327-35

Svensson J (*see* Codner et al). 2001;70:91-8

T

Tacconelli S (*see* Santini et al). 2001;70:475-83

Tan ZR (*see* Zhu et al). 2001;70:455-61

Tanaka Y (*see* Tsutsumi et al). 2001;70:121-5

Tashiro N (*see* Shintani et al). 2001;70:175-82

Taylor A (*see* Kim et al). 2001;70:189-99

Tayrouz Y, Ganssmann B, Ding R, Klingmann A, Aderjan R, Burhenne J, Haefeli WE, Mikus G. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. 2001;70:405-14

Thijssen HHW, Drittij MJ, Vervoort LMT, de Vries-Hanje JC. Altered pharmacokinetics of *R*-and *S*-acenocoumarol in a subject heterozygous for *CYP2C9*3*. 2001;70:292-8

Thompson GA (*see* Phillips et al). 2001;70:370-83
Tibboel D (*see* van der Marel et al). 2001;70:82-90
Tiupakov AN (*see* Codner et al). 2001;70:91-8
Touw DJ (*see* Mulder et al). 2001;70:546-51
Touw D (*see* Van Overmeire et al). 2001;70:336-43
Trager WF (*see* Yao et al). 2001;70:415-24
Tseng A (*see* Gallicano et al). 2001;70:149-58
Tsunoda SM, Harris RZ, Christians U, Velez RL, Freeman RB, Benet LZ, Warshaw A. Red wine decreases cyclosporine bioavailability. 2001;70:462-7
Tsuruoka S (*see* Sugimoto et al). 2001;70:518-24
Tsutsumi K, Kotegawa T, Matsuki S, Tanaka Y, Ishii Y, Kodama Y, Kuranari M, Miyakawa I, Nakano S. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and *N*-acetyltransferase activities in humans. 2001;70:121-5
Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. 2001;70:103-14
Tybring G (see Härtter et al). 2001;70:10-6
Tybring G (*see* Laine et al). 2001;70:327-35

U

Urquhart J. Demonstrating effectiveness in a post-placebo era. 2001;70:115-20
Ursing C (*see* Härtter et al). 2001;70:10-6
Utsi E (*see* Loennechen T). 2001;70:183-8

V

Vaandrager JM (*see* van der Marel et al). 2001;70:82-90
van den Anker JN (*see* de Wildt et al). 2001;70:525-31
van den Anker JN (*see* Van Overmeire et al). 2001;70:336-43
van den Bergh FAJTM (*see* Mulder et al). 2001;70:546-51
van der Linden PD (*see* Salas et al). 2001;70:561-6
van der Marel CD, van Lingen RA, Pluim MAL, Scoones G, van Dijk M, Vaandrager JM, Tibboel D. Analgesic efficacy of rectal versus oral acetaminophen in children after major craniofacial surgery. 2001;70:82-90
van Dijk M (see van der Marel et al). 2001;70:82-90
van Ltjf HJ (*see* Mulder et al). 2001;70:546-51
van Lingen RA (*see* van der Marel et al). 2001;70:82-90
Van Overmeire B, Touw D, Schepens PJC, Kearns GL, van den Anker JN. Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. 2001;70:336-43
van Rijswijk REN (*see* Kerbusch et al). 2001;70:132-41
Velez RL (*see* Tsunoda et al). 2001;70:462-7
Vergés J (*see* du Souich and Vergés). 2001;70:5-9.
Vermes I (*see* Mulder et al). 2001;70:546-51
Verstuyft C (see Becquemont et al). 2001;70:311-6
Vervoort LMT (*see* Thijssen et al). 2001;70:292-8
von Bahr C (*see* Härtter et al). 2001;70:10-6
von Richter O, Greiner B, Fromm MF, Fraser R, Omari T, Barclay ML, Dent J, Somogyi AA, Eichelbaum M. Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. 2001;70:217-27
Vontobel P (*see* Dietz et al). 2001;70:33-41

W

Walmsley S (*see* Gallicano et al). 2001;70:149-58
Wan YJY (*see* Mendoza et al). 2001;70:552-60
Wang JH, Liu ZQ, Wang W, Chen XP, Shu Y, He N, Zhou HH. Pharmacokinetics of sertraline in relation to genetic polymorphism if *CYP2C19*. 2001;70:42-7
Wang W (*see* Wang et al). 2001;70:42-7
Wang Y (*see* Yao et al). 2001;70:415-24
Wang Z, Gorski JC, Hammam MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (*Hypericum perforatum*) on human cytochrome P450 activity. 2001;70:317-26
Warshaw A (*see* Tsunoda et al). 2001;70:462-7
Wasserman GS (*see* James et al). 2001;70:280-6
Watkins PB (*see* Rivory and Watkins). 2001;70:395-6
Wellhoener P (*see* Deininger et al). 2001;70:362-9
Widén J (*see* Laine et al). 2001;70:327-35
Wilkinson GR (*see* Kim et al). 2001;70:189-99
Williams DH (*see* O'Connor-Semmes et al). 2001;70:126-31
Wood AJJ (*see* Dishy et al). 2001;70:270-9
Wu TC (*see* Chiou et al). 2001;70:305-10
Wu TC (*see* Chiou et al). 2001;70:397-8

X

Xiao F (*see* Furuta et al). 2001;70:484-92
Xie HG (*see* Kim et al). 2001;70:189-99
Xu J (*see* Mirochnick et al). 2001;70:24-32

Y

Yao C, Kunze K, Kharasch ED, Wang Y, Trager WF, Ragueneau I, Levy RH. Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. 2001;70:415-24
Yi SY (*see* Yu et al). 2001;70:228-36
Yogev R (*see* Mirochnick et al). 2001;70:24-32
Yonath H (*see* Loebstein et al). 2001;70:159-64
Yu KS, Cho JY, Shon JH, Bae KS, Yi SY, Lim HS, Jang IJ, Shin SG. Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin. 2001;70:228-36

Z

Zhan F (*see* Dishy et al). 2001;70:270-9
Zheng Y (*see* Mendoza et al). 2001;70:552-60
Zhou HH (*see* Wang et al). 2001;70:42-7
Zhou HH (*see* Zhu et al). 2001;70:455-61
Zhou S (*see* Kim et al). 2001;70:189-99
Zhu B, Ou-Yang DS, Chen XP, Huang SL, Tan ZR, He N, Zhou HH. Assessment of cytochrome P450 activity by a five-drug cocktail approach. 2001;70:455-61
Zimmermann H (*see* Kovarik et al). 2001;70:425-30

Subject index*

A

Acenocoumarol
Altered pharmacokinetics of *R*-and *S*-acenocoumarol in a subject heterozygous for *CYP2C9*3* (Thijssen et al). 2001;70:292-8

Acetaminophen
Analgesic efficacy of rectal versus oral acetaminophen in children after major craniofacial surgery (ven der Marel et al). 2001;70:82-90
Elevation of serum interleukin 8 levels in acetaminophen overdose in children and adolescents (James et al). 2001;70:280-6

Acetyltransferases
The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and *N*-acetyltransferase activities in humans (Tsutsumi et al). 2001;70:121-5

Adjuvants, immunologic
Isatoribine (USAN List No. 441). 2001;70:303

Age factors
Interindividual variability in sensitivity to warfarin-nature or nurture? (Loebstein). 2001;70:159-64

Aged
Impaired cognitive function and compliance with antihypertensives in elderly: the Rotterdam Study (Salas et al). 2001;70:561-6

Alcoholic beverages
Red wine-cisapride interaction: comparison with grapefruit juice (Offman et al). 2001;70:17-23
Red wine decreases cyclosporine bioavailability (Tsunoda et al). 2001;70:462-7

Alfentanil
A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans (Phimmasone et al). 2001;70:505-17

American Society of Clinical Pharmacology & Therapeutics
Clinical Pharmacology & Therapeutics annual report 2000 (Reidenberg and Reidenberg). 2001;70:299-301

Analgesia
Analgesic efficacy of rectal versus oral acetaminophen in children after major craniofacial surgery (ven der Marel et al). 2001;70:82-90
Gender and the placebo analgesic effect in acute pain (Averbuch and Katzper). 2001;70:287-91

Analgesics
Analgesic effects of peripherally administered opioids in clinical models of acute and chronic inflammation (Dionne et al). 2001;70:66-73
Limited sampling approach (Duvaldestin). 2001;70:493
Radolmidine hydrochloride (USAN List No. 442). 2001;70:402
Reply (Penson and Joel). 2001;70:493-4

Angioplasty
Angioplasty increases target site concentrations of ciprofloxacin in patients with arterial occlusive disease (Joukhadar et al). 2001;70:532-9

Antibiotics
Oritavancin diphosphate (USAN List No. 439). 2001;70:99

Antibodies, monoclonal
Mepolizumab (USAN List No. 443). 2001;70:496
Rovelizumab (USAN List No. 440). 2001;70:200
Ruplizumab (USAN List No. 444). 2001;70:569

Antihypertensive agents
Impaired cognitive function and compliance with antihypertensives in elderly: the Rotterdam Study (Salas et al). 2001;70:561-6

Antineoplastic agents
Irofulven (USAN List No. 442). 2001;70:402

Antipsychotic agents
Ziprasidone mesylate (USAN List No. 439). 2001;70:100

Antiviral agents
Fosamprenavir sodium (USAN List No. 442). 2001;70:402

Arterial occlusive diseases
Ecraprost (USAN List No. 442). 2001;70:401

AS-013; *see* Ecraprost

Authorship
Unmasking ghost writers (Reidenberg). 2001;70:208-9

Azimilide
A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide (Phillips et al). 2001;70:370-83

B

Bartter's disease
Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide (Nüsing et al). 2001;70:384-90

BG9588; *see* Ruplizumab

Books
Books received. 2001;70:570.

Breath tests
Erythromycin breath test (Rivory and Watkins). 2001;70:395-6
Reply (Chiou et al). 2001;70:397-8
Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization (Chiou et al). 2001;70:305-10

bu5c8; *see* Ruplizumab

C

Caffeine
Assessment of cytochrome P450 activity by a five-drug cocktail approach (Zhu et al). 2001;70:455-6
Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study (Härtter et al). 2001;70:10-6

Carbamazepine
Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs (Lapatto-Reiniluoto et al). 2001;70:255-60

Cardiomyopathy, congestive
Nesiritide citrate (USAN List No. 440). 2001;70:200

Charcoal
Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs (Lapatto-Reiniluoto et al). 2001;70:255-60

Children; *see also* Infants, premature
Analgesic efficacy of rectal versus oral acetaminophen in children after major craniofacial surgery (ven der Marel et al). 2001;70:82-90
Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children (Codner). 2001;70:91-8
Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection (Mirochnick). 2001;70: 24-32

Chlorzoxazone
Assessment of cytochrome P450 activity by a five-drug cocktail approach (Zhu et al). 2001;70:455-6

Chondroitin sulfates
Simple approach to predict the maximal effect elicited by a drug when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data (du Souich and

*July, pp. 1-102; August, pp. 103-204; September, pp. 205-304; October, pp. 305-404; November, pp. 405-496; December, pp. 497-586. Index to the ASCPT meeting abstracts is located in the February issue.

Vergés). 2001;70:5-9.

Ciprofloxacin
Angioplasty increases target site concentrations of ciprofloxacin in patients with arterial occlusive disease (Joukhadar et al). 2001;70:532-9

Cisapride
Red wine-cisapride interaction: comparison with grapefruit juice (Offman et al). 2001;70:17-23

Citrus
Effect of grapefruit juice on digoxin pharmacokinetics in humans (Becquemont et al). 2001;70:311-5
Red wine-cisapride interaction: comparison with grapefruit juice (Offman et al). 2001;70:17-23

Clarithromycin
The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentration and effects of repaglinide (Niemi et al). 2001;70:58-65

Clinical trials
Demonstrating effectiveness in a post-placebo era (Urquhart). 2001;70:115-20

Cognition; *see* Neurobehavioral manifestations

Commentaries
An open invitation for an explanation about how drug prices are set (Reidenberg). 2001;70:205-7
Demonstrating effectiveness in a post-placebo era (Urquhart). 2001;70:115-20
Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus (Tucker et al). 2001;70:103-14
Pharmacodynamic modeling of time-dependent transduction systems (Mager and Jusko). 2001;70:210-6
Pharmacogenetics, pharmacogenomics, and pharmacobiology (Kalow). 2001;70:1-4
Simple approach to predict the maximal effect elicited by a drug when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data (du Souich and Vergés). 2001;70:5-9.
Unmasking ghost writers (Reidenberg). 2001;70:208-9

Contrast media
Gadofosveset trisodium (USAN List No. 440). 2001;70:201

Coronary disease
Angioplasty increases target site concentrations of ciprofloxacin in patients with arterial occlusive disease (Joukhadar et al). 2001;70:532-9

Correspondence; *see* Letters to the Editor

Cortisol
The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids (Santini et al). 2001;70:475-83

Cyclooxygenase
The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids (Santini et al). 2001;70:475-83
Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2 (Kammerl et al). 2001;70:468-74

Cyclooxygenase inhibitors
Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide (Nüsing et al). 2001;70:384-90

Cyclosporine
Red wine decreases cyclosporine bioavailability (Tsunoda et al). 2001;70:462-7

Cytochrome P450
Altered pharmacokinetics of *R*-and *S*-acenocoumarol in a subject heterozygous for *CYP2C9*3* (Thijssen et al). 2001;70:292-8
Assessment of cytochrome P450 activity by a five-drug cocktail approach (Zhu et al). 2001;70:455-6
Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin Mulder et al). 2001;70:546-51
CYP2D6 polymorphism in a Mexican American population (Mendoza et al). 2001;70:552-60
Deficient C-oxidation of nicotine continued (Benowitz). 2001;70:567
Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients (Schmidt et al). 2001;70:446-54
Effect of high-dose lansoprazole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19 (Furuta et al). 2001;70:484-92
The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and *N*-acetyltransferase activities in humans (Tsutsumi et al). 2001;70:121-5
The effects of St John's wort (*Hypericum perforatum*) on human cytochrome P450 activity (Wang et al). 2001;70:317-26
Erythromycin breath test (Rivory and Watkins). 2001;70:395-6
Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2 (Yao et al). 2001;70:415-24
Genetic polymorphisms and functional characterization of the 5′-flanking region of the human *CYP2C9* gene: in vitro and in vivo studies (Shintani et al). 2001;70:175-82
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test (Laine et al). 2001;70:327-35
Interindividual variability in sensitivity to warfarin-nature or nurture? (Loebstein). 2001;70:159-64
Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study (Härtter et al). 2001;70:10-6
Pharmacokinetics of sertraline in relation to genetic polymorphism if *CYP2C19* (Wang et al). 2001;70:42-7
A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans (Phimmasone et al). 2001;70:505-17
Red wine decreases cyclosporine bioavailability (Tsunoda et al). 2001;70:462-7
Reply (Chiou et al). 2001;70:397-8
Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization (Chiou et al). 2001;70:305-10

D

Dapsone
Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection (Mirochnick). 2001;70: 24-32

Debrisoquin
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test (Laine et al). 2001;70:327-35

Delayed-action preparations
Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs (Lapatto-Reiniluoto et al). 2001;70:255-60

Diabetes mellitus
Losartan attenuates symptomatic and hormonal responses to hypoglycemia in humans (Deininger et al). 2001;70:362-9

Digoxin
Effect of grapefruit juice on digoxin pharmacokinetics in humans (Becquemont et al). 2001;70:311-5

Dihydroergotoxine
Erythromycin increases plasma concentrations of α-dihydroergocryptine in humans (de Mey et al). 2001;70:142-8

Doxapram
QT interval lengthening in premature infants treated with doxapram (Maillard et al). 2001;70:540-5

Drug costs
An open invitation for an explanation about how drug prices are set (Reidenberg). 2001;70:205-7

Drug development
Demonstrating effectiveness in a post-placebo era (Urquhart). 2001;70:115-20

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus (Tucker et al). 2001;70:103-14

Drug interactions; *see also* Pharmacokinetics

The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentration and effects of repaglinide (Niemi et al). 2001;70:58-65

Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin (Sugimoto et al). 2001;70:518-24

Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride (Niemi et al). 2001;70:439-45

Effect of ranitidine on the pharmacokinetics of triazolam and α-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people (O'Connor-Semmes et al). 2001;70:126-31

Erythromycin increases plasma concentrations of α-dihydroergocryptine in humans (de Mey et al). 2001;70:142-8

Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2 (Yao et al). 2001;70:415-24

Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin (Kerbusch et al). 2001;70:132-41

QTc prolongation and drugs (Henderson et al). 2001;70:567-8

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus (Tucker et al). 2001;70:103-14

A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus (Gallicano et al). 2001;70:149-58

Reply (Abernethy). 2001;70:568

Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement (Tayrouz et al). 2001;70:405-14

Ductus arteriosus, patent

Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus (Van Overmeire et al). 2001;70:336-43

Dwarfism, pituitary

Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children (Codner). 2001;70:91-8

E

Ecraprost

Ecraprost (USAN List No. 442). 2001;70:401

Elderly; *see* Aged

Electrocardiography

Lack of effect of reboxetine on cardiac repolarization (Fleishaker et al). 2001;70:261-9

QTc prolongation and drugs (Henderson et al). 2001;70:567-8

QT interval lengthening in premature infants treated with doxapram (Maillard et al). 2001;70:540-5

Reply (Abernethy). 2001;70:568

EM 574; *see* Idremcinal

Enzymes

Laronidase (USAN List No. 439). 2001;70:101

Erythromycin

Erythromycin breath test (Rivory and Watkins). 2001;70:395-6

Erythromycin increases plasma concentrations of α-dihydroergocryptine in humans (de Mey et al). 2001;70:142-8

Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin (Yu et al). 2001;70:228-36

Reply (Chiou et al). 2001;70:397-8

Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization (Chiou et al). 2001;70:305-10

Erythromycin breath test

Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients (Schmidt et al). 2001;70:446-54

Ethnic groups

Detection of one single mutation predicts thiopurine S-methyltransferase activity in a population of Saami in northern Norway (Loennechen et al). 2001;70:183-8

Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin (Yu et al). 2001;70:228-36

Ethnicity influences morphine pharmacokinetics and pharmacodynamics (Cepeda et al). 2001;70:351-61

Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications (Kovarik et al). 2001;70:247-54

Everolimus

Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment (Kovarik et al). 2001;70:425-30

Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications (Kovarik et al). 2001;70:247-54

F

Fentanyl

Analgesic effects of peripherally administered opioids in clinical models of acute and chronic inflammation (Dionne et al). 2001;70:66-73

Fluvoxamine

Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2 (Yao et al). 2001;70:415-24

Fosamprenavir sodium

Fosamprenavir sodium (USAN List No. 442). 2001;70:402

Fosveset

Fosveset (USAN List No. 443). 2001;70:496

Furomine

Furomine (USAN List No. 442). 2001;70:401

Furosemide

Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2 (Kammerl et al). 2001;70:468-74

G

Gadofosveset trisodium

Gadofosveset trisodium (USAN List No. 440). 2001;70:201

Gastric acidity

Effect of high-dose lansoprazole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19 (Furuta et al). 2001;70:484-92

Gastrointestinal motility

Idremcinal (USAN List No. 441). 2001;70:303

Gemfibrozil

Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride (Niemi et al). 2001;70:439-45

Genes

Altered pharmacokinetics of *R*-and *S*-acenocoumarol in a subject heterozygous for *CYP2C9*3* (Thijssen et al). 2001;70:292-8

Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity (Alves et al). 2001;70:165-74

Genes, MDR

Identification of functionally variant *MDR1* alleles among European Americans and African Americans. 2001;70:189-99

Glimepiride

Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride (Niemi et al). 2001;70:439-45

Glucocorticoids, synthetic

The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids (Santini et al). 2001;70:475-83

GW 433908A; *see* Fosamprenavir sodium

H

Heavy metals
Heavy metals in traditional Chinese medicines: a systematic review (Ernst and Coon). 2001;70:497-504
Heroin
Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics (Rentsch et al). 2001;70:237-46
HIV
A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus (Gallicano et al). 2001;70:149-58
Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection (Mirochnick). 2001;70: 24-32
Hu23F2G; *see* Rovelizumab
***Hypericum* sp.**
Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin (Sugimoto et al). 2001;70:518-24
The effects of St John's wort (*Hypericum perforatum*) on human cytochrome P450 activity (Wang et al). 2001;70:317-26
Hyperprostaglandin E syndrome
Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide (Nüsing et al). 2001;70:384-90
Hypoglycemia
Losartan attenuates symptomatic and hormonal responses to hypoglycemia in humans (Deininger et al). 2001;70:362-9
Hyponatremia
Lixivaptan (USAN List No. 444). 2001;70:569

I

Ibuprofen
Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus (Van Overmeire et al). 2001;70:336-43
Ibutamoren mesylate
Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children (Codner). 2001;70:91-8
IC351; *see* Tadalafil
Idremcinal
Idremcinal (USAN List No. 441). 2001;70:303
Ifosfamide
Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin (Kerbusch et al). 2001;70:132-41
Ilodecakin
Ilodecakin (USAN List No. 441). 2001;70:304
Immunosuppressive agents
Median effect analysis of efficacy versus adverse effects of immunosuppressants (Kahan and Kramer). 2001;70:74-81
Immusine™; *see* Isatoribine
Infants, premature; *see also* Children
Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus (Van Overmeire et al). 2001;70:336-43
Pharmacokinetics and metabolism of intravenous midazolam in preterm infants (de Wildt et al). 2001;70:525-31
QT interval lengthening in premature infants treated with doxapram (Maillard et al). 2001;70:540-5
Inflammation
Analgesic effects of peripherally administered opioids in clinical models of acute and chronic inflammation (Dionne et al). 2001;70:66-73
Insulin-like growth factor I
Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children (Codner). 2001;70:91-8
Interleukins
Elevation of serum interleukin 8 levels in acetaminophen overdose in children and adolescents (James et al). 2001;70:280-6
Intestinal absorption
Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs (Lapatto-Reiniluoto et al). 2001;70:255-60
Intestines
Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique (von Richter et al). 2001;70:217-27
Irofulven
Irofulven (USAN List No. 442). 2001;70:402
Isatoribine
Isatoribine (USAN List No. 441). 2001;70:303
Isomerism
Stereoselective pharmacokinetics of ketamine: *R*(-)-ketamine inhibits the elimination of *S*(-)-ketamine (Ihmsen et al). 2001;70:431-8

K

Ketamine
Stereoselective pharmacokinetics of ketamine: *R*(-)-ketamine inhibits the elimination of *S*(-)-ketamine (Ihmsen et al). 2001;70:431-8
Ketoconazole
Lack of effect of reboxetine on cardiac repolarization (Fleishaker et al). 2001;70:261-9
Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin (Kerbusch et al). 2001;70:132-41
Kidney transplantation
Median effect analysis of efficacy versus adverse effects of immunosuppressants (Kahan and Kramer). 2001;70:74-81
Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications (Kovarik et al). 2001;70:247-54

L

L 163191; see Ibutamoren mesylate
Lansoprazole
Effect of high-dose lansoprazole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19 (Furuta et al). 2001;70:484-92
Laronidase
Laronidase (USAN List No. 439). 2001;70:101
Letters to the Editor
Deficient C-oxidation of nicotine continued (Benowitz). 2001;70:567
Erythromycin breath test (Rivory and Watkins). 2001;70:395-6
Limited sampling approach (Duvaldestin). 2001;70:493
QTc prolongation and drugs (Henderson et al). 2001;70:567-8
Reply (Abernethy). 2001;70:568
Reply (Chiou et al). 2001;70:397-8
Reply (Penson and Joel). 2001;70:493-4
LeukArrest™; *see* Rovelizumab
Levodopa
Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[^{18}F]levodopa positron emission tomography in patients with Parkinson's disease (Dietz et al). 2001;70:33-41
Ligands
Fosveset (USAN List No. 443). 2001;70:496
Furomine (USAN List No. 442). 2001;70:401
Liver
Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique (von Richter et al). 2001;70:217-27
Liver cirrhosis
Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment (Kovarik et al). 2001;70:425-30
Liver function tests
Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study (Härtter et al). 2001;70:10-6
Liver transplantation
Early postoperative erythromycin breath test correlates with hepatic

cytochrome P4503A activity in liver transplant recipients (Schmidt et al). 2001;70:446-54

Lixivaptan
Lixivaptan (USAN List No. 444). 2001;70:569

Loperamide
Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement (Tayrouz et al). 2001;70:405-14

Loratadine
QTc prolongation and drugs (Henderson et al). 2001;70:567-8
Reply (Abernethy). 2001;70:568

Losartan
Losartan attenuates symptomatic and hormonal responses to hypoglycemia in humans (Deininger et al). 2001;70:362-9

LY 333328; *see* Oritavancin diphosphate

M

Medicine, herbal
Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin (Sugimoto et al). 2001;70:518-24
The effects of St John's wort (*Hypericum perforatum*) on human cytochrome P450 activity (Wang et al). 2001;70:317-26
Heavy metals in traditional Chinese medicines: a systematic review (Ernst and Coon). 2001;70:497-504

Melatonin
Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study (Härtter et al). 2001;70:10-6

Mephenytoin
Assessment of cytochrome P450 activity by a five-drug cocktail approach (Zhu et al). 2001;70:455-6

Mepolizumab
Mepolizumab (USAN List No. 443). 2001;70:496

Metabolism
Deficient C-oxidation of nicotine continued (Benowitz). 2001;70:567

Methadone
Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate (Boulton et al). 2001;70:48-57

Methylprednisolone
The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids (Santini et al). 2001;70:475-83

Metoprolol
Assessment of cytochrome P450 activity by a five-drug cocktail approach (Zhu et al). 2001;70:455-6

Mexican Americans
CYP2D6 polymorphism in a Mexican American population (Mendoza et al). 2001;70:552-60

MGI 114; *see* Irofulven

Midazolam
Assessment of cytochrome P450 activity by a five-drug cocktail approach (Zhu et al). 2001;70:455-6
Pharmacokinetics and metabolism of intravenous midazolam in preterm infants (de Wildt et al). 2001;70:525-31

Miosis
A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans (Phimmasone et al). 2001;70:505-17

MK 0677; *see* Ibutamoren mesylate

Models
Median effect analysis of efficacy versus adverse effects of immunosuppressants (Kahan and Kramer). 2001;70:74-81
Pharmacodynamic modeling of time-dependent transduction systems (Mager and Jusko). 2001;70:210-6
A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide (Phillips et al). 2001;70:370-83
Simple approach to predict the maximal effect elicited by a drug when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data (du Souich and Vergés). 2001;70:5-9.

Models, animal
Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique (von Richter et al). 2001;70:217-27

Morphine
Analgesic effects of peripherally administered opioids in clinical models of acute and chronic inflammation (Dionne et al). 2001;70:66-73
Ethnicity influences morphine pharmacokinetics and pharmacodynamics (Cepeda et al). 2001;70:351-61

Morphine glucuronides
Limited sampling approach (Duvaldestin). 2001;70:493
Reply (Penson and Joel). 2001;70:493-4

MP-1549; *see* Furomine

MPV-2426; *see* Radolmidine hydrochloride

MS 32520; *see* Gadofosveset trisodium

MS 328168A; *see* Fosveset

N

Natrecor(r); *see* Nesiritide citrate

Nefazodone
QTc prolongation and drugs (Henderson et al). 2001;70:567-8
Reply (Abernethy). 2001;70:568

Nesiritide citrate
Nesiritide citrate (USAN List No. 440). 2001;70:200

Neurobehavioral manifestations
Impaired cognitive function and compliance with antihypertensives in elderly: the Rotterdam Study (Salas et al). 2001;70:561-6

Nicotine
Deficient C-oxidation of nicotine continued (Benowitz). 2001;70:567

Nifedipine
Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin (Yu et al). 2001;70:228-36

Nimesulide
Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide (Nüsing et al). 2001;70:384-90

Nitric oxide
The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men (Dishy et al). 2001;70:270-9

Nortriptyline
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test (Laine et al). 2001;70:327-35

O

Oritavancin diphosphate
Oritavancin diphosphate (USAN List No. 439). 2001;70:99

Overdose
Elevation of serum interleukin 8 levels in acetaminophen overdose in children and adolescents (James et al). 2001;70:280-6

P

Pain
Analgesic effects of peripherally administered opioids in clinical models of acute and chronic inflammation (Dionne et al). 2001;70:66-73
Gender and the placebo analgesic effect in acute pain (Averbuch and Katzper). 2001;70:287-91

Pain, postoperative
Analgesic efficacy of rectal versus oral acetaminophen in children after major craniofacial surgery (ven der Marel et al). 2001;70:82-90

Parkinson disease
Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[^{18}F]levodopa positron emission tomography in patients with Parkinson's disease (Dietz et al). 2001;70:33-41

Paroxetine
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharma-

cokinetics and the debrisoquin test (Laine et al). 2001;70:327-35

Patient compliance

Impaired cognitive function and compliance with antihypertensives in elderly: the Rotterdam Study (Salas et al). 2001;70:561-6

Pharmacogenetics

Pharmacogenetics, pharmacogenomics, and pharmacobiology (Kalow). 2001;70:1-4

Pharmacokinetics; *see also* Drug interactions

Altered pharmacokinetics of *R*-and *S*-acenocoumarol in a subject heterozygous for *CYP2C9*3* (Thijssen et al). 2001;70:292-8

Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics (Rentsch et al). 2001;70:237-46

Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique (von Richter et al). 2001;70:217-27

Effect of grapefruit juice on digoxin pharmacokinetics in humans (Becquemont et al). 2001;70:311-5

Effect of rifampicin and tobacco smoking on the pharmacokinetics of ropivacaine (Jokinen et al). 2001;70:344-50

Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin (Yu et al). 2001;70:228-36

Ethnicity influences morphine pharmacokinetics and pharmacodynamics (Cepeda et al). 2001;70:351-61

Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus (Van Overmeire et al). 2001;70:336-43

Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment (Kovarik et al). 2001;70:425-30

Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[^{18}F]levodopa positron emission tomography in patients with Parkinson's disease (Dietz et al). 2001;70:33-41

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus (Tucker et al). 2001;70:103-14

Pharmacokinetics and metabolism of intravenous midazolam in preterm infants (de Wildt et al). 2001;70:525-31

Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate (Boulton et al). 2001;70:48-57

A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide (Phillips et al). 2001;70:370-83

Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection (Mirochnick). 2001;70: 24-32

Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications (Kovarik et al). 2001;70:247-54

Red wine decreases cyclosporine bioavailability (Tsunoda et al). 2001;70:462-7

Stereoselective pharmacokinetics of ketamine: *R*(-)-ketamine inhibits the elimination of *S*(-)-ketamine (Ihmsen et al). 2001;70:431-8

Pharmacology, clinical

Simple approach to predict the maximal effect elicited by a drug when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data (du Souich and Vergés). 2001;70:5-9.

Phenytoin

Genetic polymorphisms and functional characterization of the 5′-flanking region of the human *CYP2C9* gene: in vitro and in vivo studies (Shintani et al). 2001;70:175-82

Severe phenytoin intoxication in a subject homozygous for *CYP2C9*3* (Brandolese et al). 2001;70:391-4

Placebos

Demonstrating effectiveness in a post-placebo era (Urquhart). 2001;70:115-20

Gender and the placebo analgesic effect in acute pain (Averbuch and Katzper). 2001;70:287-91

Poisoning

Heavy metals in traditional Chinese medicines: a systematic review (Ernst and Coon). 2001;70:497-504

Severe phenytoin intoxication in a subject homozygous for *CYP2C9*3* (Brandolese et al). 2001;70:391-4

Polymorphism (genetics)

Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin Mulder et al). 2001;70:546-51

CYP2D6 polymorphism in a Mexican American population (Mendoza et al). 2001;70:552-60

Detection of one single mutation predicts thiopurine S-methyltransferase activity in a population of Saami in northern Norway (Loennechen et al). 2001;70:183-8

Genetic polymorphisms and functional characterization of the 5′-flanking region of the human *CYP2C9* gene: in vitro and in vivo studies (Shintani et al). 2001;70:175-82

Identification of functionally variant *MDR1* alleles among European Americans and African Americans. 2001;70:189-99

Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity (Alves et al). 2001;70:165-74

Pharmacogenetics, pharmacogenomics, and pharmacobiology (Kalow). 2001;70:1-4

Pharmacokinetics of sertraline in relation to genetic polymorphism if *CYP2C19* (Wang et al). 2001;70:42-7

Severe phenytoin intoxication in a subject homozygous for *CYP2C9*3* (Brandolese et al). 2001;70:391-4

Population studies

A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide (Phillips et al). 2001;70:370-83

Pravastatin

Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin (Sugimoto et al). 2001;70:518-24

Pregnancy

The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and *N*-acetyltransferase activities in humans (Tsutsumi et al). 2001;70:121-5

Prescription fees

An open invitation for an explanation about how drug prices are set (Reidenberg). 2001;70:205-7

R

Racial stocks

Identification of functionally variant *MDR1* alleles among European Americans and African Americans. 2001;70:189-99

Radolmidine

Radolmidine hydrochloride (USAN List No. 442). 2001;70:402

Ranitidine

Effect of ranitidine on the pharmacokinetics of triazolam and α-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people (O'Connor-Semmes et al). 2001;70:126-31

Reboxetine

Lack of effect of reboxetine on cardiac repolarization (Fleishaker et al). 2001;70:261-9

Receptors, vasopressin

Lixivaptan (USAN List No. 444). 2001;70:569

Renin-angiotensin system

Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2 (Kammerl et al). 2001;70:468-74

Repaglinide

The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentration and effects of repaglinide (Niemi et al). 2001;70:58-65

Respiratory insufficiency

Limited sampling approach (Duvaldestin). 2001;70:493

Reply (Penson and Joel). 2001;70:493-4

rhVEGF; *see* Telbermin

Rifabutin

A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human

immunodeficiency virus (Gallicano et al). 2001;70:149-58

Rifampin
Effect of rifampicin and tobacco smoking on the pharmacokinetics of ropivacaine (Jokinen et al). 2001;70:344-50
Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin (Kerbusch et al). 2001;70:132-41

Ritonavir
A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus (Gallicano et al). 2001;70:149-58
Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement (Tayrouz et al). 2001;70:405-14

Rofecoxib
Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2 (Kammerl et al). 2001;70:468-74

Ropivacaine
Effect of rifampicin and tobacco smoking on the pharmacokinetics of ropivacaine (Jokinen et al). 2001;70:344-50

Rostaporfin
Rostaporfin (USAN List No. 439). 2001;70:100

Rovelizumab
Rovelizumab (USAN List No. 440). 2001;70:200

Ruplizumab
Ruplizumab (USAN List No. 444). 2001;70:569

S

St John's wort; *see Hypericum* sp.

Saquinavir
A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus (Gallicano et al). 2001;70:149-58

SB-240563; *see* Mepolizumab

Sertraline
Pharmacokinetics of sertraline in relation to genetic polymorphism if *CYP2C19* (Wang et al). 2001;70:42-7

Sex
Gender and the placebo analgesic effect in acute pain (Averbuch and Katzper). 2001;70:287-91

Sexual dysfunction
Tadalafil (USAN List No. 440). 2001;70:201

Sildenafil
The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men (Dishy et al). 2001;70:270-9

Simvastatin
Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin Mulder et al). 2001;70:546-51
Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin (Sugimoto et al). 2001;70:518-24

Smoking
Effect of rifampicin and tobacco smoking on the pharmacokinetics of ropivacaine (Jokinen et al). 2001;70:344-50

SnET2; *see* Rostaporfin

Somatotropin
Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children (Codner). 2001;70:91-8

Substance abuse
Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics (Rentsch et al). 2001;70:237-46

T

Tadalafil
Tadalafil (USAN List No. 440). 2001;70:201

Telbermin
Telbermin (USAN List No. 441). 2001;70:304

Tenovil™; *see* Ilodecakin

Terfenadine
QTc prolongation and drugs (Henderson et al). 2001;70:567-8
Reply (Abernethy). 2001;70:568

Theophylline
Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs (Lapatto-Reiniluoto et al). 2001;70:255-60
Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2 (Yao et al). 2001;70:415-24

Thiopurine methyltransferase
Detection of one single mutation predicts thiopurine S-methyltransferase activity in a population of Saami in northern Norway (Loennechen et al). 2001;70:183-8
Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity (Alves et al). 2001;70:165-74

Tin etiopurpurin
Rostaporfin (USAN List No. 439). 2001;70:100

Tomography, emission-computed
Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[^{18}F]levodopa positron emission tomography in patients with Parkinson's disease (Dietz et al). 2001;70:33-41

Triazolam
Effect of ranitidine on the pharmacokinetics of triazolam and α-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people (O'Connor-Semmes et al). 2001;70:126-31

V

Vascular permeability factor recombinant
Telbermin (USAN List No. 441). 2001;70:304

Vasodilation
The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men (Dishy et al). 2001;70:270-9

Verapamil
Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs (Lapatto-Reiniluoto et al). 2001;70:255-60

Vitamin K
Interindividual variability in sensitivity to warfarin-nature or nurture? (Loebstein). 2001;70:159-64

W

Warfarin
Interindividual variability in sensitivity to warfarin-nature or nurture? (Loebstein). 2001;70:159-64

WAY-VPA-985; *see* Lixivaptan

X

Xanthine oxidase
The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and *N*-acetyltransferase activities in humans (Tsutsumi et al). 2001;70:121-5

Z

Zeldox™ IM; *see* Ziprasidone mesylate

Ziprasidone mesylate
Ziprasidone mesylate (USAN List No. 439). 2001;70:100